Allostera raised $17 million in VC financing

Guest Contributor
July 29, 2009

Montreal-based Allostera Pharma Inc has raised $17 million in series ‘A' financing to develop a new class of drugs based on the firm's proprietary Module X platform technology. So-called allosteramers use modified peptides with highly specific targets that can be developed rapidly and can be taken orally, which may make them more widely accepted than injectable drugs. The latest financing comes from iNovia Capital, Genesys Capital, BDC Capital with GO Capital and Fonds Bio-Innovation sec. Allostera's technology was developed between 2002 and 2005 by co-founder and chief scientific officer Dr Sylvain Chemtob and graduate student Christiane Quiniou — researchers at CHU Ste Justine, a hospital affiliated with the Univ of Montreal. Incorporated in 2005, early development was funded by several organizations including Gestion Univalor LP, the Canadian Institute of Health Research's Proof-of-Principal program, debt from the Centre québecois de valorisation des biotechnologies, convertible debt from MSBi Valorisation and the Government of Quebec....

Other News

Events For Leaders in
Science, Tech, Innovation, and Policy

Discuss and learn from those in the know at our virtual and in-person events.

See Upcoming Events

You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in


By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.